Abstract: An infusion set includes a base (221) and a flexible catheter (242) movable from a first catheter position disposed substantially entirely within the base (221) to a second catheter position in which a free end of the catheter (242) is disposed externally of the base (221). An introducer needle (234) is located within the catheter (242) and is movable between a first introducer needle position disposed substantially entirely within the base (221) and a second introducer needle position in which a free end of the introducer needle (234) is disposed externally of the bases (221). A spring (281) is activated to move the catheter (242) from the first to the second catheter position and the introducer needle (234) from the first to the second introducer needle position to facilitate insertion of the catheter (242).

Abstract: Methods and systems include ways to implement change analysis of an automated production line including at least one robot. Monitoring a plurality of operating parameters associated with the automated production line including the at least one robot is followed by recording at least one change to the plurality of operating parameters. A notification is then provided identifying the at least one change to the plurality of operating parameters. The notification can include mapping the at least one change onto a graphical representation of the automated production line, thereby identifying a portion of the automated production line affected by the at least one change. As a result, at least one of the operating parameters can be adjusted in response to the notification. An action can also be performed in response to the notification. In this manner, the change analysis can optimize operation of the automated production line.

Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.

Abstract: Described embodiments relate to methods, systems and computer program product for scheduling retrieval of candidate information from a first entity system at the predicted time. The method comprises determining a dataset associated with historical information issued by a first entity, wherein the dataset comprises a plurality of entries, each entry comprising an information date; determining a period of successful retrieval of information issued by the first entity, or a period of issuance of information by the first entity, based on the information dates of the plurality of entries in the dataset; determining a predicted time of issuance of future information by the first entity based on the determined period; and scheduling retrieval of candidate information from a first entity system at the predicted time.

Abstract: A method for verifying an electronic circuit design includes detecting a first issue in a register transfer level description of the electronic circuit design and receiving a selection to waive the first issue. The method also includes capturing the selection to waive the first issue in a memory, detecting, by a processing device, a second issue while generating a netlist or gate level description of the electronic circuit design, and based on determining that the selection to waive the first issue indicated in the memory applies to the second issue, suppressing or ignoring the second issue.

Abstract: A microelectromechanical systems (MEMS) accelerometer is provided, comprising a substrate disposed in a plane defined by a first axis and a second axis perpendicular to the first axis; a first proof mass and a second proof mass coupled to the substrate and configured to translate in opposite directions of each other along a third axis perpendicular to the first and second axes; and at least one lever coupling the first proof mass to the second proof mass, wherein, the MEMS accelerometer is configured to detect acceleration along the third axis via detection of translation of the first and second proof masses along the third axis; and the MEMS accelerometer exhibits symmetry about the first and second axes.

Abstract: An RF-shielded window apparatus may comprise a primary panel and a secondary panel. The primary panel may include a primary RF shield layer disposed between a primary backing substrate and a protective layer. The secondary panel may include a secondary backing substrate and a secondary RF shield layer. The first panel element and the second panel element may be secured to one another such that the primary RF shield layer, the secondary RF shield layer and the protective layer are collectively disposed between the primary backing substrate and the secondary backing substrate. The primary RF shield layer and the secondary RF shield layer may be in electrically-conductive communication with one another. A panel joining strip may facilitate the securement of the first panel to the second panel, and the electrically-conductive communication may be at least in part by way of the panel joining strip. Associated manufacturing methods are also disclosed.

Abstract: Methods and apparatus for vaporizing liquid from a liquid source into the surrounding environment, are disclosed, where the apparatus comprises at least one manifold comprising at least one liquid port formed by a through-hole and at least one ridge structure, wherein the liquid port is in fluid communication with the liquid source and the one ridge structure At least one vaporization port is included in a planar structure connecting a first side of the structure to a second side, in fluid communication with the at least one ridge structure and the surrounding environment, wherein fluid flow through the liquid and vaporization ports is substantially perpendicular to the plane of the structure, and the ridge structures are substantially parallel to the plane of the structure. At least one heating element is present that is in thermal communication to the at least one vaporization port and at least one ridge structure.

Abstract: Provided is a ureteral stent comprising certain amount of ethylene-vinyl acetate polymer and a certain amount of an additive selected from barium sulfate, bismuth subcarbonate, bismuth oxychloride, a polyolefin elastomer, a thermoplastics elastomer, and a mixture thereof. The provided stent may have multiple layers such as inner layer and outer layer with each layer having different elastic modulus. Also provided is a method of making the aforementioned ureteral stent and a method of using the ureteral stent in treating kidney or bladder related diseases.

Abstract: A barrier device for preventing the growth of weeds and grass in various outdoor areas. The barrier device is made of weatherproof materials such as vinyl or rubber and comes in the form of a roll, enabling users to cut the desired length along perforation lines according to their requirements. The barrier device features a rectilinear shape with a horizontal member for laying over the desired area, a pair of vertical members extending downwards from the longitudinal edges of the horizontal member, the vertical members form a 90-degree angle with the horizontal member, providing a secure grip and preventing shifting or displacement of the barrier device. A plurality of recessed grooves or slits on the horizontal member facilitate water drainage to prevent water accumulation on the barrier device and enable application of weed killer under the horizontal member.

Abstract: A method is provided for treating or preventing symptoms of asthma in a subject in need thereof by administering a corticosteroid pharmaceutical composition to a subject qualified for over-the-counter access to the corticosteroid pharmaceutical composition. In some embodiments, the corticosteroid pharmaceutical composition includes a class B corticosteroid, a glucocorticosteroid, budesonide, ciclesonide, fluticasone furoate, mometasone furoate, fluticasone propionate, or beclomethasone dipropionate.

Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti-hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes N,N-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.

Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.

Abstract: A virtual assistant/chatbot to improve clinical workflow for home renal replacement therapies is disclosed herein. A virtual assistant/chatbot includes a patient-facing user interface configured to enable a patient to engage in a virtual chat session by typing, speaking, or otherwise providing information regarding a patient request or issue related to their renal replacement therapy. The virtual assistant/chatbot also includes a backend server-based system configured to provide logic to respond to a patient's requests. The logic defines a sequence of questions and answers for resolving patient queries. The sequence of assistant/chatbot questions and patient answers may be configured in a node arrangement such that certain patient answers/requests lead to additional questions for additional information from a patient.

Abstract: A board game assembly includes a game board that has game board indicia printed thereon comprising imagery of a floor plan of a house. A plurality of identity boards is provided and each of the identity boards is assigned to a respective player. A pair of dice is provided for rolling during the course of game play. A plurality of playing cards is provided which includes a set of hint cards, a set of character cards, a set of ability cards, a set of quest cards and a set of memory cards. A selected number of the playing cards is dealt to each of the respective players and is positioned on a respective card location on the identity board that is assigned to the respective player. A plurality of game pieces is each assigned to a respective player and each of the game pieces is positionable on the game board to indicate a location of a character assigned to the respective player.

Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.

Abstract: Among other things, the present disclosure relates to re-purposing used lithium-ion batteries. The present disclosure includes treating an electrode using a solvent prior to electrochemically relithiating the electrode. In some embodiments, the relithiation may be done using a roll-to-roll device, wherein the electrode may be secured on a first pin and a second pin, then it may be unwound and submerged in an electrolyte solution. Lithium ions may be inserted into the electrode using a voltage. The layer of lithium may provide lithium ions to the electrode.

Abstract: The present disclosure provides for methods and systems for separating ultrafine particulate pollutants from aqueous suspensions. The present disclosure provide for methods and systems that can reduce the amount of ultrafine particulate pollutants from aqueous solutions, for example storm water runoff, which are not readily or easily removed using current state of the art techniques. In general, methods of the present disclosure provide for removing a portion of target ultrafine particulate pollutants using magnetic nanoparticles, which form aggregates with the ultrafine particulate pollutants. After a time period a magnetic field is applied and the aggregate can be separated from the aqueous suspension. Subsequently, the aggregates can be broken down and the magnetic nanoparticles recycled or reused while the ultrafine particulate contaminants are further processed, recycled, or disposed of.